SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)

Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the research at the end of the third infusion of bevacizumab.

Patients will perform a home blood pressure self-measurement over three days and will collect urine over 24 hours prior to the start of each bevacizumab infusion at cycles 1, 2 and 3. Blood pressure measurements will also be performed during each bevacizumab infusion and blood tests will be performed before each infusion to measure the following biomarkers:

• Salt consumption as estimated by 24-hour natriuresis measured before each of the first 3 infusions
• 24 hours aldosterone excretion measured before the first and third infusions
• plasma methoxylated derivatives measured before the first and third infusions
• NTproBNP measured before the first and third infusions
• 24 hours urinary free cortisol measured before the first and third infusions
• bevacizumab trough concentration measured before the first three bevacizumab infusion

Inclusion criteria

• Adult patient
• With a solid cancer for which a treatment with bevacizumab (Avastin®) is indicated in accordance with its marketing authorization

Exclusion criteria

• Renal cancer
• Recent changes in antihypertensive treatment(s) in the last month, with the exception for diuretics where treatment stability of at least 3 months will be required
• Patients who do not wish to participate to the study